Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NR082 gene therapy for ND4 mutation-associated Leber hereditary optic neuropathy
CTR20243372Phase 3Active
- Sponsor
- Neurophth
- Start
- Sep 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esonadogene mvoparvovec in Leber hereditary optic neuropathy (LHON) (2 arms), sponsored by Neurophth. Primary endpoint: Proportion of subjects with improvement of at least 0.3 LogMAR in BCVA of the study eye from baseline. Started Sep 2024; status: active.
02
Drugs
esonadogene mvoparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on CTR20243372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243372.